{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T00:56:40Z","timestamp":1649033800096},"reference-count":28,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>A 69-year-old man presents with a Dynamic International Prognostic Scoring System (DIPSS) intermediate-risk 2 post polycythemia vera myelofibrosis with significant splenomegaly, 30 pound weight loss, constitutional symptoms, and 2% peripheral blood blasts. He has no other significant past medical history and no other major comorbid conditions. You are asked by the hematology fellow you are supervising whether or not treating this patient with a Janus kinase (JAK) inhibitor will decrease major morbid events.<\/jats:p>","DOI":"10.1182\/asheducation-2015.1.649","type":"journal-article","created":{"date-parts":[[2016,9,15]],"date-time":"2016-09-15T15:23:25Z","timestamp":1473953005000},"page":"649-651","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Evidence for Janus kinase (JAK) inhibitors for the prevention of major morbid events in patients with myeloproliferative neoplasms (MPNs)"],"prefix":"10.1182","volume":"2015","author":[{"given":"Naveen","family":"Pemmaraju","sequence":"first","affiliation":[{"name":"Department of Leukemia, MD Anderson Cancer Center, Houston, TX; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruben","family":"Mesa","sequence":"additional","affiliation":[{"name":"Division of Hematology & Medical Oncology, Mayo Clinic in Arizona, Scottsdale, AZ"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2019111520593289800_B1","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"key":"2019111520593289800_B2","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2013-02-485888","article-title":"Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis","volume":"122","author":"Cervantes","year":"2013","journal-title":"Blood"},{"key":"2019111520593289800_B3","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1182\/blood-2013-09-527903","article-title":"Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients","volume":"123","author":"Geyer","year":"2014","journal-title":"Blood"},{"issue":"7","key":"2019111520593289800_B4","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1038\/leu.2014.5","article-title":"Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis","volume":"28","author":"Tabarroki","year":"2014","journal-title":"Leukemia"},{"key":"2019111520593289800_B5","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N Engl J Med"},{"key":"2019111520593289800_B6","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs","volume":"30","author":"Emanuel","year":"2012","journal-title":"J Clin Oncol"},{"key":"2019111520593289800_B7","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N Engl J Med"},{"key":"2019111520593289800_B8","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"key":"2019111520593289800_B9","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med"},{"key":"2019111520593289800_B10","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2013-02-485888","article-title":"Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis","volume":"122","year":"2013","journal-title":"Blood"},{"key":"2019111520593289800_B11","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1056\/NEJMp1114649","article-title":"Toward patient-centered drug development in oncology","volume":"369","author":"Basch","year":"2013","journal-title":"N Engl J Med"},{"key":"2019111520593289800_B12","first-page":"264","article-title":"Patient-reported outcomes are changing the landscape in oncology care: challenges and opportunities for payers","volume":"6","author":"Zagadailov","year":"2013","journal-title":"Am Health Drug Benefits"},{"key":"2019111520593289800_B13","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1517\/14656566.2014.913024","article-title":"Janus kinase inhibitors for the treatment of myeloproliferative neoplasms","volume":"15","author":"Rosenthal","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"2019111520593289800_B14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/2040620712461047","article-title":"Comprehensive review of JAK inhibitors in myeloproliferative neoplasms","volume":"4","author":"Sonbol","year":"2013","journal-title":"Therapeut Adv Hematol"},{"key":"2019111520593289800_B15","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1517\/13543784.2013.774373","article-title":"Investigational Janus kinase inhibitors","volume":"22","author":"Tam","year":"2013","journal-title":"Expert Opin Investig Drugs"},{"key":"2019111520593289800_B16","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.leukres.2013.05.009","article-title":"The burden of symptoms in myelofibrosis: from patient-reported outcomes to health economics","volume":"37","author":"Pieri","year":"2013","journal-title":"Leuk Res"},{"key":"2019111520593289800_B17","doi-asserted-by":"crossref","first-page":"LBA7006","DOI":"10.1200\/jco.2015.33.15_suppl.lba7006","article-title":"Results of the PERSIST-1 phase III study of pacritinib (PAC) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia-myelofibrosis (PET-MF) [abstract]","volume":"33","author":"Mesa","year":"2015","journal-title":"J Clin Oncol"},{"key":"2019111520593289800_B18","article-title":"Patient-reported outcomes (PROS) in persist-1: A randomized, multi-country phase III trial of the JAK2 inhibitor pacritinib (PAC) vs. best available therapy (BAT) in myelofibrosis","author":"Mesa","year":"2015","journal-title":"European Hematology Association"},{"key":"2019111520593289800_B19","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/cncr.22365","article-title":"The burden of fatigue and quality-of-life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients","volume":"109","author":"Mesa","year":"2007","journal-title":"Cancer"},{"key":"2019111520593289800_B20","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.leukres.2009.01.035","article-title":"The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality-of-life and symptomatic response to treatment in myelofibrosis","volume":"33","author":"Mesa","year":"2009","journal-title":"Leuk Res"},{"key":"2019111520593289800_B21","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.2012.44.4489","article-title":"Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial","volume":"31","author":"Mesa","year":"2013","journal-title":"J Clin Oncol"},{"key":"2019111520593289800_B22","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.leukres.2013.04.017","article-title":"Progressive burden of myelofibrosis in untreated patients: assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study","volume":"37","author":"Mesa","year":"2013","journal-title":"Leuk Res"},{"key":"2019111520593289800_B23","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1182\/blood-2011-10-387787","article-title":"Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera","volume":"119","author":"Alvarez-Larran","year":"2012","journal-title":"Blood"},{"key":"2019111520593289800_B24","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/cncr.28441","article-title":"A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea","volume":"120","author":"Verstovsek","year":"2014","journal-title":"Cancer"},{"issue":"8","key":"2019111520593289800_B25","first-page":"575","article-title":"Ruxolitinib proves superior to best available therapy in a prospective, randomized, phase 3 study (RESPONSE) in patients with polycythemia vera resistant to or intolerant of hydroxyurea","volume":"39","author":"Vannucchi","year":"2014","journal-title":"19th Congress of the European Hematology Association (EHA)"},{"key":"2019111520593289800_B26","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111520593289800_B27","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol"},{"issue":"21","key":"2019111520593289800_B28","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1182\/blood.V122.21.664.664","article-title":"BMS-911543, a selective JAK2 inhibitor: a multicenter phase 1\/2a study in myelofibrosis","volume":"122","author":"Roberts","year":"2013","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2015\/1\/649\/1250323\/bep00115000649.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2015\/1\/649\/1250323\/bep00115000649.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T04:40:54Z","timestamp":1573879254000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2015\/1\/649\/306118\/Evidence-for-Janus-kinase-JAK-inhibitors-for-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,5]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2015.1.649","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,5]]}}}